Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 4:00PM CDT
Auxilium (AUXL) announced that Sobi has filed for an extension of the label for Xiapex in the EU to include the indication of Peyronie's disease.
Bristol-Myers Up on Nivolumab News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 9:45AM CDT
Bristol-Myers' (BMY) nivolumab performed very well in a late-stage study.
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 5:10PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in phase II/III study.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
British Columbia to Reimburse TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis
CNW Group - Wed Jun 25, 10:00AM CDT
Biogen Idec Canada announces today that TECFIDERATM (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver
PR Newswire - Wed Jun 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRTX, DLTR, CAR, R, and BIIB.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders
at The Street - Tue Jun 24, 9:45AM CDT
Stocks with insider trader activity include BIIB, FDS and GCO
Stocks with Upgraded Broker Ratings - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jun 24, 3:05AM CDT
Stocks with Upgraded Broker Ratings - Screen of the Week
AbbVie, Shire Give Bullish Guidance Amid Buyout Talk
at Investor's Business Daily - Mon Jun 23, 10:24AM CDT
Big pharma AbbVie (ABBV) raised its 2014 earnings guidance Monday, sending the company's stock up 1.5% in morning trading on the stock market. Meanwhile, AbbVie's buyout target Shire (SHPG) detailed its own bullish guidance in explaining to investors...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Fri Jun 20, 9:32AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human
Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...
Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...